Viewing nowCombinationSambica HCT Tablet 10/40/12.5 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg +1 more
Tablet · Prescription medication · Combination
Samsung Pharm Co., Ltd.

MFDS item code 201902022 · Approved 2019.04.03 · Insurance code 642307620
Treatment of essential hypertension not controlled with amlodipine and olmesartan combination therapy
The combination therapy of amlodipine and olmesartan medoxomil is used in cases where blood pressure is not adequately controlled in patients with essential hypertension. This medication helps to dilate blood vessels and lower blood pressure, thereby reducing the burden on the cardiovascular system. Using both drugs together enhances blood pressure control and helps reduce the risk of complications such as heart disease or stroke. Therefore, this combination therapy plays an important role in managing hypertension and is used to reliably lower patients' blood pressure.
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not adequately controlled with amlodipine and olmesartan medoxomil combination therapy, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 5/40mg or with this medicine at 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine at 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 10/40mg or with this medicine at 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine at 5/40/25mg or 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Since experience with this medicine in elderly patients, particularly those aged 75 years and older, is very limited, monitor patients very carefully when administering this medicine.
Safety and efficacy have not been established in pediatric patients under 18 years of age; therefore, administration of this medicine is not recommended.
This medication can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergies to this medication or its components, those with certain heart, kidney, or liver diseases, pregnant women, and nursing mothers should not take this medication. Patients with reduced blood volume or impaired kidney function may experience side effects such as hypotension; therefore, their condition should be closely monitored before administration and during treatment. This medication has a strong blood pressure-lowering effect, which can lead to dizziness or orthostatic hypotension, so caution is advised when driving or operating dangerous machinery. During the use of this medication, regular tests of electrolyte levels in the blood are necessary to ensure that imbalances of potassium, sodium, and calcium do not occur. In particular, the diuretics included in this medication may affect blood sugar regulation in diabetic patients, so adjustments to diabetes medication doses may be necessary. This medication may interact with other drugs; therefore, especially when taken with lithium, non-steroidal anti-inflammatory drugs (NSAIDs), or other antihypertensives, consultation with a healthcare professional is advised. Photosensitivity reactions may occur, so care should be taken to avoid excessive exposure to sunlight or ultraviolet rays, and any abnormal skin symptoms should be reported immediately. This medication can also be used in the elderly, but dosage adjustments may be necessary in cases of decreased kidney or liver function, and in cases of overdose, symptoms such as hypotension and palpitations may occur, requiring immediate treatment. The use of this medication during breastfeeding is not recommended; if it must be taken, stopping breastfeeding is advisable. Safety and efficacy have not been established in pediatric patients, so it is advisable not to administer this medication to children. During the use of this medication, regular medical check-ups are necessary to carefully monitor for any adverse reactions or changes in symptoms.
Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, loss of appetite, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimuli, anxiety, mood changes, sleep disorders, orthostatic dizziness, syncope, taste disorders, hypertonia, sensory impairment, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, appetite loss, tremor, visual disturbances, decreased tear production, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina pectoris, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, abdominal distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like reaction, pustular rash, exfoliative dermatitis, sweating, photosensitivity reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, hives, muscle cramps, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, increased urinary frequency, acute renal failure, hematuria, urination disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, apathy, edema, pain, facial edema, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatinine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, altered consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, acute respiratory distress syndrome
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is also recommended to store it at room temperature, between 1 and 30 degrees Celsius. This helps maintain the medication's effectiveness for a longer period.
Grayish-red round film-coated tablet
30 tablets (10 tablets/Alu-Alu × 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg +1 more
Tablet · Prescription medication · Combination
Samsung Pharm Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg +1 more
Tablet · Prescription medication · Combination
Daicel Corporation (Co., Ltd.)
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
HanKook Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg +1 more
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.